earnings
confidence high
sentiment positive
materiality 0.75
OptimizeRx Q1 revenue up 11% to $21.9M; raises FY 2025 guidance
OptimizeRx Corp
2025-Q1 EPS reported
-$0.12
revenue$21,928,000
- Q1 revenue $21.9M (+11% YoY); gross profit $13.3M (+9% YoY).
- GAAP net loss ($2.2M) or ($0.12)/share; non-GAAP net income $1.5M ($0.08)/diluted share.
- Adjusted EBITDA $1.5M vs. ($0.3M) in prior-year Q1.
- FY 2025 guidance raised: revenue $101M–$106M, adjusted EBITDA $13M–$15M.
- Cash and investments $16.6M at March 31; net revenue retention 114%.